drugset / Trial / NCT04870073

Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery

NCT04870073

RandomizedFactorialSingle-blindTreatment

Summary

Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red blood cells (hematocrit), physiological ions and coagulation factors that can contribute to impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to evaluate whether retrograde autologous priming and/or mannitol are superior to conventional priming alone.

Timeline

Start
2022-09-21
Primary completion
2022-09-21
Completion
2022-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent 0.3 g/kg Other